Clovis Oncology (CLVS) Misses Q4 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Clovis Oncology Announces 2016 Operating Results
February 22, 2017 4:05 PM ESTRubraca (rucaparib) approved and launched in the U.S. on December 19, 2016 for the treatment of advanced BRCA-mutant ovarian cancer $266.2M in cash, cash equivalents and available for sale securities at December 31, 2016 $487.4M in adjusted cash, cash equivalents and available for sale securities at December 31, 2016 as adjusted for the January 2017 financing proceeds of $221.2 million Rucaparib MAA submission accepted and under review; CHMP opinion anticipated Q4 2017 Establishing EU commercial organization Data from ARIEL3 pivotal rucaparib maintenance study expected... More
